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Nearly 50% of subjects of coronary artery disease suffer from coronary microvascular
dysfunction. Various etiopathogenetic factors have been proposed by different workers but
no hypothesis can explain the genesis of microvascular angina in all patients. We have
made an attempt to review the literature to find caveats in our knowledge so that future
studies can be better designed.
Copyright © 2014, Cardiological Society of India. All rights reserved.Since it's recognition, microvascular angina was considered
synonymous with cardiac syndrome X resulting in several
controversies. Cardiac syndromeX is defined as typical angina
with positive stress test but normal coronary angiogram.1
Now it is clear that there are several causes for angina or
angina like discomfort with normal coronary angiogram.
Microvascular angina is a subset with specific etiopatho-
genesis and therapeutic implications.2,3 Coronary microvas-
cular dysfunction is suspected by a positive physical or
pharmacological stress test using electrocardiography/cardiac
MRI/SPECT or PET.4 Coronary flow reserve less than 2.5 on
adenosine induced maximal hyperemia suggests microvas-
cular dysfunction.5 Coronary flow reserve in left anterior
descending coronary artery can be assessed non-invasively
using transthoracic Doppler echocardiography.2 Invasively,
coronary microvascular dysfunction can be evaluated by
index of microcirculatory resistance.6 Several issues, howev-
er, need to be addressed for further refinement of diagnosis
and decision about management strategy in an individual
patient..
ciety of India. All rights1. Documentation of myocardial ischemia
Objective evidence of myocardial ischemia, however, has not
beenobserved in all cases inspite of ischemia like ST-T changes
onexerciseelectrocardiograms.7Reasons for the lowsensitivity
of presently available non invasive methods (stress test, echo-
cardiography & radio-isotope perfusion imaging) to detect
ischemia in cases of microvascular angina are not clear.8,9
It appears that sensitivity and specificity of different
methods needs re-evaluation in the context of microvascular
angina. Etiopathogenesis, prognosis andmanagementmay be
different in patients with evidence of myocardial ischemia
than in those without evidence of myocardial ischemia.102. Role of abnormal pain perception
Abnormal pain perception has been proposed as an underly-
ing mechanism for chest pain in patients with microvascularreserved.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 7 8e6 8 1 679angina.4,11 High incidence of anxiety and panic attacks and
relief with imipramine, transcutaneous stimulation and spi-
nal cord stimulation are considered to support such mecha-
nism. However, there are some difficulties in accepting this
hypothesis.
(i) Most of the studies were performed in cases of syn-
drome X. Coronary microvascular dysfunction was not
documented.
(ii) As the studies included cases of syndrome X, more fe-
males were studied by default. Anxiety and panic at-
tacks are more frequent in females.
(iii) Most of the studies have shown partial symptomatic
relief in some patients. There is no objective evidence of
improvement in microvascular dysfunction. Symp-
tomatic relief could be because of placebo effect.
(iv) Imipramine is an antidepressant. It is possible that re-
sponders had occult depression with somatic localiza-
tion rather than microvascular angina.
It is possible that some patients of microvascular angina
(specially females) have abnormal pain perception as a co-
morbidity. It is also possible that acute adrenergic drive during
a panic attack can produce transient microvascular spasm.
These possibilities need documentation.3. Role of autonomic dysfunction
Increased adrenergic activity has been observed in some pa-
tients of cardiac syndrome X.12 However, coronary adrenergic
hyperreactivity has not been documented.13 Plasma cate-
cholamine levels have been found to be normal14 and alpha
blockade has not been shown to increase myocardial blood
flow in patients of cardiac syndrome X.15 It has been postu-
lated that parasympathetic impairment could produce
microvascular dysfunction through its' influence on endo-
thelial function.16 However, Frobert et al17 found no evidence
of autonomic dysfunction in patients of cardiac syndrome X
with positive exercise test. Etiological significance of auto-
nomic dysfunction is, therefore, not clear. Stress cardiomy-
opathy has been shown to be associated with coronary
microvascular dysfunction in the affected area in small
number of selected patients.18 However, ischemia itself can
also increase microvascular resistance.19 Inspite of these
limitations and conflicting observations in literature, some
possibilities deserve further evaluation.
(i) Some subjects can have hyperdynamic myocardial
response to beta adrenergic stimulation.20 This may
produce chest pain specially, in subjects with abnormal
pain perception.
(ii) Transient increase in adrenergic activity can produce
coronary microvascular spasm.2 Transient autonomic
dysfunction has been shown to precede ST segment
depression in patients with syndrome X.21
(iii) It is possible that sympatho-vagal imbalance can pro-
duce increased coronary microvascular resistance at
rest and decreased dilatory capacity during stress. Such
pathophysiology can produce effort angina.4. Role of inflammation
Higher levels of circulating intercellular adhesion molecule 
1 and high sensitivity CRP have been observed in some
cases.22,23 Some issues, however, need to be clarified.
(i) There is no evidence that subjects with presence of in-
flammatory markers are more prone to have isolated
coronary microvascular dysfunction without involve-
ment of epicardial coronaries.
(ii) There is no evidence of any correlation between pres-
ence, duration and magnitude of abnormality in in-
flammatory markers and coronary microvascular
dysfunction.
(iii) Is coronary microvascular dysfunction present only in
patients having higher levels of inflammatory markers
due to systemic vasculitis? Will inflammatory process
not involving vessels also produce coronary microvas-
cular dysfunction?
(iv) Will management of systemic inflammation retard or
revert coronary microvascular dysfunction?
(v) Do other markers of inflammation e.g. raised ESR or
gammaglobulins also correlate with coronary micro-
vascular dysfunction?
5. Role of cardiovascular risk factors
(i) Systemic hypertension is associated with interstitial
fibrosis and myocyte hypertrophy.24 These factors can
also produce angina with normal coronary angiograms.
How to differentiate these possibilities from microvas-
cular angina?
(ii) Diabetes mellitus is associated with microvascular
dysfunction.25 However, diabetics also have impaired
myocardial metabolic function26 which may produce
angina even in absence of microvascular dysfunction.
How to differentiate?
(iii) Common cardiovascular risk factors are frequently
present in patients with coronary microvascular
dysfunction.27e29 However, there is poor correlation
between risk factors and severity of coronary micro-
vascular dysfunction.30e32 On the contrary, coronary
microvascular spam has been found to be more com-
mon in white, females with lower body mass index,
lower frequency of smoking and relatively higher levels
of HDL.33,34
(iv) Initial impression of higher incidence in females was
derived from studies of patients of syndrome X. Studies
comparing coronary flow reserve in response to aden-
osine have, however, found similar incidence in both
sexes.35It is also not clear if there are any other sex
differences in microvascular angina.
(v) Reason for isolated/dominant initial localization of pa-
thology to microcirculation in some patients and
epicardial coronaries in other patients is not clear. Ge-
netic predisposition of microcirculation might be
important.36,37
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Coronary microvascular dysfunction has been found to be
associated with migraine headache,38 impairment of flow
mediated vasodilation of peripheral vessels,39 progressive
involvement of epicardial coronaries40 and higher incidence
of stroke on follow up.41 It is possible that coronary micro-
vascular dysfunction is a part of generalized endothelial
dysfunction. Evaluation of endothelial functions in different
vascular territories along with evaluation of coronary micro-
vascular functions can clarify the issue.7. Role of stem cells, progenitor cells
Endothelial progenitor cells and circulating endothelial cells
have the potential to repair vascular endothelium.42
Decreased number of CD 34 cells and significant impairment
of their function have been found in women with microvas-
cular dysfunction.43 Some investigators have noted interac-
tion between vascular smooth muscle cells and endothelial
progenitor cells.44 Further studies are required to find the
significance of these observations in patients with docu-
mented microvascular angina.8. Conclusion
“Microvascular angina” includes several disorders with het-
erogeneous etiopathogenesis. Diagnosis, management and
prognosis are likely to differ depending on the underlying
etiopathogenesis. Future studies should be designed to find
exact etiopathogenesis in an individual patient.Conflicts of interest
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